Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. NCT05104866 (ClinicalTrials.gov).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2023-0188 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in China.
Front Pharmacol
August 2025
Medical Insurance Office, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Background: The present study aimed to evaluate the cost-effectiveness of pembrolizumab combined with chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer from the perspective of the Chinese healthcare system.
Methods: A Markov model was developed to track patients' transitions over 3-week cycles and evaluate the health and economic outcomes over a 10-year horizon for the two competing treatments. The survival data were gathered from the KEYNOTE-355 trial, and cost and utility values were obtained from the published studies.
The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.
Lung Cancer
August 2025
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China; Guangzhou Institute of Respiratory Health, Guangzhou, C
Background: Large cell neuroendocrine carcinoma (LCNEC) represents a rare and unique type of lung tumor with an unfavorable prognosis. It is essential to summarize the treatment modalities and prognosis for inoperable stage III and IV LCNEC, explore the role of frontline immunotherapy, and examine the stratification role of the Lung Immune Prognostic Index (LIPI) and its relationship with the tumor microenvironment (TME).
Methods: This study retrospectively analyzed 160 patients with inoperable lung LCNEC (L-LCNEC) admitted to three hospitals from December 2012 to November 2023.
Comparing the Efficacy and Safety of IC-ICCRT-IO With CT-CCRT for Unresectable Locally Advanced ESCC: A Retrospective Analysis.
J Immunother
September 2025
Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Laoshan, Qingdao, Shandong, China.
The present study was designed to evaluate the efficacy and safety of induction chemotherapy combined with a PD-1 inhibitor (sintilimab) followed by concurrent chemoradiotherapy (CCRT) plus sintilimab and subsequent maintenance (IC-ICCRT-IO) in patients with unresectable locally advanced esophageal squamous carcinoma (ESCC) compared with induction chemotherapy followed by CCRT without PD-1 inhibitors (CT-CCRT) using propensity score matching (PSM). Data collected from patients with histologically confirmed, inoperable ESCC treated with IC-ICCRT-IO or CT-CCRT were retrospectively analyzed-a 1:1 PSM with a caliper of 0.05 balanced potential biases.
View Article and Find Full Text PDFInterventional management of chest wall sarcomatoid carcinoma mimicking breast cancer metastasis: A case report.
Medicine (Baltimore)
August 2025
Department of Interventional Treatment, Beijing No. 6 Hospital, Beijing, China.
Rationale: Breast cancer patients have an increased risk of developing second primary malignancies, with lung cancer accounting for approximately 5% of cases. Differentiating between metastatic disease and a second primary malignancy remains a diagnostic challenge.
Patient Concerns: A 45-year-old woman with a history of triple-negative breast cancer presented with a newly detected chest wall nodule during routine follow-up.
The Incidence of Abemaciclib-induced Interstitial Lung Disease: A Single-center Retrospective Study in Japan.
Kobe J Med Sci
August 2025
Department of Breast Surgery, Kakogawa Central City Hospital, Kakogawa, Japan.
Background And Aim: Abemaciclib, a CDK4/6 inhibitor, is used for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Interstitial lung disease (ILD) is a frequent adverse event of abemaciclib, particularly in Asian patients, though limited information is available on its incidence and risk factors. This study aimed to identify the incidence and risk factors of abemaciclib-induced ILD through a single-center retrospective analysis.
View Article and Find Full Text PDF